- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02772965
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (COMBINE)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overall study duration: 6 years Multi-center study: up to 42 centers
Number of subjects: 425 Duration of treatment for each subject: up to 156 weeks (3 years)
The primary endpoint is percent of patients who experienced treatment failure over time.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's of Alabama
-
-
California
-
Alto, California, United States, 94304
- Stanford Children's Health
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale-New Haven Children's Hospital
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Nemours Children's Health System - Wilmington
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Health System - Jacksonville
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital
-
Orlando, Florida, United States, 32827
- Nemours Children's Health System - Orlando
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Children's Healthcare of Atlanta at Egleston/Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
Boston, Massachusetts, United States, 02114
- MassGeneral Hospital for Children
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan | CS Mott Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
Saint Louis, Missouri, United States, 63104
- Cardinal Glennon Children's Medical Center
-
Saint Louis, Missouri, United States, 63110
- St. Louis Children's Hospital | Washington University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Children's Hospital and Medical Center Omaha
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Kravis Children's Hospital
-
Syracuse, New York, United States, 13210
- Upstate Golisano Children's Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28203
- Levine Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies & Children's Hospital
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, United States, 45404
- Dayton Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma University Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- The University of Vermont Children's Hospital
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Pediatric Specialists Of Virginia
-
Norfolk, Virginia, United States, 23507
- Children's Hospital of the King's Daughters
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pediatric Crohn's Disease (PCD) patients, < 21 years of age, ≥20 kg, initiating anti-TNF therapy with infliximab or adalimumab (including biosimilars).
- Diagnosis of Crohn's Disease (CD) established confirmed by the treating clinician, and established by standard clinical criteria (radiography, endoscopy, histology).
- Ability to provide parental permission and child assent (where applicable), or adult consent for patients ages 18-20.
Exclusion Criteria:
- Prior use of anti-TNF or other biological therapy for CD
- Lack of stable home address that study medications can be mailed to
- Anticipated short length of follow up at study center (plans for family to move, transition to adult GI (gastrointestinal) provider, etc.). Patients expected to leave practice < 12 months from enrollment should not be enrolled.
- Concurrent pelvic or abdominal abscess. A recent history of abdominal or pelvic abscess, which is controlled, does not exclude the subject.
- Prior intra-abdominal surgery without a clinically significant relapse (i.e. patients starting on anti-TNF for post-op prophylaxis or for endoscopic recurrence only should not be included)
- Receipt of a live virus vaccine within the last 30 days
- Pregnancy, planning to become pregnant, or high risk of pregnancy as determined by the local investigator
- Breastfeeding
- Refusal to stay abstinent or utilize 2 forms of birth control while on study medication (for female patients)
- BMI > 98% for gender and age
- Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years). A recent history of basal cell or squamous cell carcinoma, which is considered surgically cured, does not exclude the subject.Those with a recent history of colonic adenoma or dysplastic lesions should be excluded.
- Known high alcohol consumption (more than seven drinks per week)
- Patients with serum albumin < 2.5 g/dl
- Patients with white blood cell count (WBC) < 3.0 x109th/L
- Patients with platelet count < 100 x109th/L
- Patients with initial elevation of liver enzymes (AST or ALT) > 1.5 times above normal limit
- Patients with known active infection with Clostridium difficile (C. difficile) (untreated infection based on clinician assessment does not apply to colonization or infection controlled with current or prior treatment.)
- Patients with pre-existing hepatic disease
- Patients with pre-existing renal dysfunction (creatinine > 0.8 for children age<10, creatinine > 1.2 mg/dl for children age 10-18, and creatinine > 1.5 mg/dl for adults age 18 years and older).
- Patients with a pre-existing chronic lung disease other than well controlled asthma
- Current treatment with one of the following drugs: Probenecid (Probalan), Acitretin (Soriatane), Streptozocin (Zanosar), Azathioprine (Imuran, Azasan), 6-mercaptopurine (Purinethol, Purixan)
- Other concerns about the patient/family's ability to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methotrexate
Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose. Folic Acid (1 mg) daily |
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Other Names:
|
Placebo Comparator: Sugar pill (placebo)
Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose. Folic Acid (1 mg) daily |
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Participants Experiencing Treatment Failure
Time Frame: From randomization until treatment failure, assessed up to 3 years.
|
Treatment failure is defined as follows:
|
From randomization until treatment failure, assessed up to 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Patient Reported Outcome Measurement and Information System (PROMIS ) Pain Interference T-score-52 Weeks
Time Frame: Weeks 52 from randomization
|
T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average pain interference and scores below 50 represent lower than average pain interference. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6. The investigators will compare the mean of PROMIS Pain Interference T-scores at week 52 between the treatment groups. |
Weeks 52 from randomization
|
Mean Patient Reported Outcome Measurement and Information System (PROMIS ) Pain Interference T-score-week 104
Time Frame: 104 weeks from randomization
|
T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average pain interference and scores below 50 represent lower than average pain interference. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6. The investigators will compare the mean of PROMIS Pain Interference T-scores at week 104 between the treatment groups |
104 weeks from randomization
|
Mean PROMIS (Patient Reported Outcome Measurement and Information System) Fatigue T Score-week 52
Time Frame: Week 52 from randomization
|
T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average fatigue and scores below 50 represent lower than average fatigue. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6. The investigators will compare the mean of PROMIS Fatigue T-scores at week 52 between the treatment groups |
Week 52 from randomization
|
Mean PROMIS (Patient Reported Outcome Measurement and Information System) Fatigue T Score-week 104
Time Frame: 104 weeks from randomization
|
T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average fatigue and scores below 50 represent lower than average fatigue. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6. The investigators will compare the mean of PROMIS Fatigue T-scores at week 104 between the treatment groups |
104 weeks from randomization
|
Percent of Patients With Positive Anti-TNF Antibody
Time Frame: Between 6 months and 2 years from randomization
|
Percent of patients with positive anti-TNF antibody will be compared between the two treatment groups using the chi-squared test.
|
Between 6 months and 2 years from randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Michael D Kappelman, MD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- 16-0476
- PCS-1406-18643 (Other Grant/Funding Number: Patient-Centered Outcomes Research Institute (PCORI))
- 1U19AR069525-01 (U.S. NIH Grant/Contract)
- PCD-MTX-001 (Other Identifier: UNC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Crohn's Disease
-
Rhode Island HospitalEnrolling by invitationGastrointestinal Diseases | Colitis | Pediatric Disorder | Pediatric Crohns Disease | Procedural SequelaeUnited States
-
Hôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France; NestléUnknownCrohn's Disease | PediatricFrance
-
Children's Hospital Los AngelesCompleted
-
Hospices Civils de LyonNot yet recruitingCrohn Disease | Pediatric Crohns DiseaseFrance
-
University of North Carolina, Chapel HillUniversity of Amsterdam; Crohn's and Colitis FoundationRecruitingCrohn Disease | Pediatric Crohns DiseaseNetherlands, United States, Canada, Israel
-
Laura MacknerChildren's Hospital Medical Center, CincinnatiRecruitingInflammatory Bowel Diseases | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited States
-
Klinikum Westbrandenburg GmbHUnknown
-
Azienda Policlinico Umberto ICompletedPediatric | Colon Capsule EndoscopyItaly
-
McMaster UniversityCompletedPediatric Ulcerative Colitis | Pediatric Crohns Disease | Pediatric Inflammatory Bowel DiseasesCanada
-
Vanderbilt University Medical CenterCompleted
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted